Kexing Biopharm (688136.SH) disclosed the third quarter report for 2024, achieving operating revenue for the first three quarters...
Zhixun Finance APP News, Kexing Biopharm (688136.SH) disclosed the third quarter report for 2024, achieving operating revenue of 1.038 billion yuan in the first three quarters, a year-on-year growth of 7.15%; net income attributable to the mother 17.18 million yuan, turning loss into profit year-on-year; non-net income 24.24 million yuan, turning loss into profit year-on-year; basic earnings per share 0.09 yuan.